Trial reportPediatric cardiology2023
The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis.
Trial report in Pediatric cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02741115 (Fontan Udenafil Exercise Longitudinal Assessment Trial), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Fontan Patients with a Systemic Left Ventricle Have Greater Exercise Capacity than those with a Systemic Right Ventricle: A Systematic Review and Meta-Analysis.Pediatric cardiology · 2026Pooled it
- Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium.Circulation · 2026Article
- Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation.Journal of the American Heart Association · 2025Article
- How cardiac output is controlled in a Fontan circulation: an update.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- The Future of the Fontan Circulation: A Call for Innovation and Collaboration.JACC. Case reports · 2025Article
- Exercise Performance: A Fontan Phenotype Predictive of Long-Term Survival.JACC. Advances · 2024Article
- A retrospective review of sildenafil in the Australia and New Zealand Fontan registry: indications and treatment responses.International journal of cardiology. Congenital heart disease · 2024Article
- Five decades of Fontan palliation: What have we learned? What should we expect?The Journal of international medical research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Pediatric Heart Network's Fontan Udenafil Exercise Longitudinal (FUEL) Trial (Mezzion Pharma Co. Ltd., NCT02741115) demonstrated improvements in some measures of exercise capacity and in the myocardial performance index following 6 months of treatment with udenafil (87.5 mg twice daily). In this post hoc analysis, we evaluate whether subgroups within the population experienced a differential effect on exercise performance in response to treatment. The effect of udenafil on exercise was evaluated within subgroups defined by baseline characteristics, including peak oxygen consumption (VO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.